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 ABSTRACT
The most common HCV-related nephropathy is membranoproliferative glomerulonephritis (MPGN), 
usually in the context of cryoglobulinaemia. The treatment of this entity is not consensual and represents 
a challenge to clinicians. We report a case of membranoproliferative glomerulonephritis associated with 
cryoglobulinaemia type II in a 46-year-old Caucasian male recipient of a deceased kidney transplant in 
2010. His baseline serum creatinine (SCr) was 1.1 mg/dl. After three years post-transplantation, he pre-
sented with nephritic syndrome in association with renal function impairment (SCr – 2.1 mg/dl). The 
laboratory tests revealed positive rheumatoid factor, hypocomplementaemia and a positive cryocrit with 
type II cryoglobulinaemia. Antinuclear autoantibodies and anti-double stranded DNA antibodies were 
negative. Despite the presence of anti-HCV antibodies, the viral load remained undetectable. The allograft 
biopsy showed lesions compatible with membranoproliferative glomerulonephritis, with staining in the 
immunofluorescence for granular IgM and C3 and no C4d. He was treated with methylprednisolone pulses 
followed by oral prednisolone in association with rituximab. Two months after the last dose of rituximab, 
the SCr improved to 1.27 mg/dl, the proteinuria decreased and serum C3 levels normalized. Cryoglo-
globulins and rheumatoid factor became negative and HCV RNA remained undetectable. The patient was 
lost for follow-up. In our case, the treatment with rituximab resulted in a favourable outcome, although 
a longer follow-up period may be needed to evaluate the clinical response, since other studies reported 
high relapse rates.
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 INTRODUCTION
Post-transplantation morbidity in renal transplant 
patients with hepatitis C virus (HCV) infection may be 
partially explained by the risk of de novo or recurrent 
HCV associated glomerulopathies1-5, which can lead 
to allograft dysfunction. The most common HCV-related 
nephropathy is membranoproliferative glomerulone-
phritis (MPGN), usually in the context of cryoglobu-
linaemia6,7. Other glomerular diseases have also been 
reported, such as membranous nephropathy, minimal 
change disease, thrombotic microangiopathy, acute 
transplant glomerulopathy and chronic transplant glo-
merulopathies1,4,5. Patients may have clinical mani-
festations of cryoglobulinaemia, including palpable 
purpura, arthralgias, neuropathy, and weakness, how-
ever the triad of purpura, asthaenia and arthralgia is 
present in only 30% of the cases 8,9. Renal manifesta-
tions include nephrotic or non-nephrotic proteinuria, 
haematuria and hypertension in 80% of the patients.
Treatment of this entity is a complex issue, non-
consensual and represents a challenge to clinicians. 
Rituximab, a human mouse chimeric monoclonal 
antibody directed against CD20 antigen on B lym-
phocytes, has recently proved to be effective on the 
treatment of this entity, however, the ideal dosage 
of this drug has not yet been defined.
 CASE REPORT
A 46-year-old Caucasian male with a history of 
chronic kidney disease associated with HCV-related 
membranoproliferative glomerulonephritis (MPGN), had 
a cadaveric renal transplant in 2010. The patient did 
not receive any previous antiviral therapy. His baseline 
serum creatinine after transplantation was 1.1 mg/dl. 
He had a history of illicit drug abuse (cocaine and 
heroin) with methadone replacement therapy since 
2006. His maintenance immunosuppressive treatment 
consisted of tacrolimus (Advagraf®) 5.5 mg/day, myco-
phenolate mofetil (MMF) 500 mg twice a day and pred-
nisolone 5 mg/day. In September 2013, his SCr raised 
to 1.6 mg/dl, he had proteinuria in the nephrotic range 
(4g/day), active urinary sediment, legs oedema and 
severe de novo hypertension. He was admitted in the 
hospital for further investigation. Physical examination 
on admission revealed oedema of the legs and ankles 
and hypertension (180/100 mmHg), without palpable 
purpura, arthritis, cutaneous ulcers or peripheral neu-
ropathy. Renal function progressively worsened to a 
maximum of SCr of 2.12 mg/dl. The other laboratory 
tests showed an elevated rheumatoid factor (16 IU/ml) 
and hypocomplementaemia with C3 and C4 reduction 
(23 mg/dl and 8.0 mg/dl, respectively). Antinuclear 
autoantibodies (ANAs) and anti-double stranded DNA 
(dsDNA) antibodies were negative. Cryocrit was positive 
 RESUMO
A glomerulonefrite membranoproliferativa com crioglobulinemia associa-se frequentemente à infeção pelo vírus 
da hepatite C. O tratamento desta entidade não é consensual e representa um desafio para os clínicos. Apre-
sentamos um caso de glomerulonefrite membranoproliferativa associada a crioglobulinemia tipo II num doente 
do sexo masculino de 46 anos portador de enxerto renal de dador cadavérico desde 2010. O seu valor de cre-
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reumatoide positivo, crioglobulinemia tipo II, hipocomplementemia. Os anticorpos antinuclear e anti-double stranded 
DNA foram negativos. Apesar da presença de anticorpos anti-HCV a carga vírica era indetectável. A biópsia do 
enxerto renal demonstrou lesões compatíveis com glomerulonefrite membranoproliferativa com depósitos granu-
lares para IgM e C3 e marcação com C4d negativa na imunofluorescência. Iniciou terapêutica com pulsos de 
metilprednisolona seguido posteriormente por prednisolona oral em associação com rituximab. Dois meses após 
a última dose de Rituximab o valor de creatinina melhorou para 1,27 mg/dl, a proteinúria diminuiu e os níveis 
de C3 normalizaram. O doseamento de crioglobulinas e de fator reumatoide foi negativo e a carga vírica do VHC 
permaneceu indetectável. Foi perdido o follow-up do doente. No nosso caso o tratamento com Rituximab associou-
se a uma melhoria clínica. Um período de follow-up maior é necessário para a monitorização clínica uma vez que 
as taxas de recidiva são elevadas de acordo com estudos publicados na literatura.
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(21 mcg/mL) and cryoglobulin characterization revealed 
type II cryoglobulinaemia. The serological markers were 
negative for HIV and HBV infection, with positive anti-
HCV antibodies. HCV viral load was undetectable (< 15 
UI/ml), however, HCV RNA was detected in cryoglobulin. 
Transaminases were normal.
An allograft biopsy was performed and showed 
lesions compatible with MPGN. Immunofluorescence 
staining showed granular IgM and C3 and trace 
deposits of C1q and IgG within the basal membrane. 
C4d staining was negative.
There were no other organ manifestations of cryo-
globulinaemia. Immunosuppressive treatment was 
started with methylprednisolone pulses (500 mg/day 
for three days) followed by a rapid taper to 20 mg/
day of oral prednisolone in association with intrave-
nous Rituximab 375 mg/m2 every 3 weeks (2 infusions). 
Two months after the last dose of rituximab, hyperten-
sion resolved, serum creatinine improved (1.27 mg/
dl), proteinuria decreased (2g/day), serum C3 levels 
returned to normal while C4 levels had a discreet 
improvement (51 mg/dl; 9.0 mg/dl, respectively), rheu-
matoid factor became negative, cryoglobulins were 
cleared and HCV RNA remained undetectable. There 
were no infectious complications during the treatment 
with rituximab. After the last infusion, the patient 
restarted use of cocaine and was lost for follow-up.
 DISCUSSION
Treatment of HCV-related MPGN associated with type 
II CG in a renal transplant patient is a complex issue 
and remains a challenge. The management is critical 
and the main purpose is to improve long-term allograft 
survival. The reported rate of recurrence of MPGN is this 
group of patients varies from 20-30% and the incidence 
of graft loss may exceed 15%10. The main goal of anti-
retroviral therapy before transplantation is to achieve 
sustained viral response, because the risk of hepatic 
and extra hepatic complications is reduced. The HCV is 
an independent risk factor for graft loss and proteinuria 
after transplantation4,5,12. Higher HCV viral loads may 
result in more immune complexes and increased deposi-
tion of viral complexes in the kidney and a higher risk 
for HCV-related nephropathy1,13 on the contrary, a sus-
tained virological response (serum HCV-RNA undetect-
able) may reduce post-transplant recurrence of HCV 
glomerulonephritis, as well as chronic allograft nephropa-
thy1,13,14. Anti-HCV antibodies and HCV RNA have been 
detected in the great majority of patients with mixed 
cryoglobulinaemia, and the concentration of HCV RNA 
in cryoprecipiate is 1000 times higher than in serum7,15.
The treatment of this entity is a complex, non-
consensual issue and represents a challenge to clini-
cians. The general initial approach includes immuno-
suppression with corticosteroids in association with 
cyclophosphamide or Rituximab or/and plasmapher-
esis, followed by treatment of the underlying disease. 
Antiviral therapy is not routinely recommended in a 
renal transplant patient because of concerns regarding 
allograft rejection. According to KDIGO clinical practice 
guidelines of 2008, treatment with interferon should 
be reserved to patients with fibrosing cholestatic 
hepatitis or life-threatening vasculitis16. Ribavirin 
monotherapy seems to improve liver enzymes level, 
but is not associated with beneficial effect on liver 
histology neither in virological clearance. The IFN in 
combination with ribavirin is effective in two-thirds 
of patients after a minimum therapy of six months, 
but it is poorly tolerated and results in graft dysfunc-
tion in a significant number of patients16,17.
Protease inhibitors (telaprevir and boceprevir) are 
emerging as a third feature of combination therapy with 
peg INF-α and ribavirin. Two major trials (SPRINT- 2 
and ADVANCE), demonstrated the efficacy in achieving 
higher sustained viral response (75% – telaprevir; 69% 
– boceprevir) in patients with genotype 118,19. To date, 
there are no studies of this therapy in renal transplant 
and randomized controlled trials are needed20. Its use 
is not recommended in patients with renal transplant.
The use of Rituximab (the monoclonal anti-CD 20 
antibody) therapy in the setting of renal transplanta-
tion is multiple and includes desensitization and 
ABO-incompatible transplantation, treatment of 
humoral rejection, post-transplant lymphoprolifera-
tive disorders and recurrent or de novo glomerular 
diseases. There have been several case reports and 
studies showing the effectiveness of Rituximab in 
the treatment of glomerular diseases, however, more 
randomized studies are needed 7,8,12,21,22.
We describe a case of membranoproliferative glo-
merulonephritis associated with type II cryoglobulinaemia 
in a renal transplant patient with hepatitis C. The asso-
ciation of this virus with mixed cryoglobulinaemia in our 
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case may be explained by the presence of circulating 
anti-HCV antibodies, and the presence of HCV-RNA in 
the cryoprecipitate, suggesting that HCV exerted a patho-
genic role in the formation of cryoglobulins. This diag-
nostic was surprising since the patient presented with 
sustained negative viral load, but there are other reported 
cases in the literature of HCV-related glomerulonephritis 
in patients with undetectable HCV-RNA23.
In our case, the patient presented with a severe renal 
disease that demanded a more aggressive approach. 
Recently Rituximab had been used in a few studies of 
cryoglobulinaemic MPGN associated with HCV infection 
and the results were encouraging. The IgM autoantibody 
producing B lymphocytes appears to be depleted pref-
erentially, which may explain the efficacy of this drug 
in this disease24. Rituximab seems to be as least as 
efficient as cyclophosphamide, is also better tolerated 
and, in contrast to cyclophosphamide, does not enhance 
HCV replication7. For these reasons we decided to treat 
the patient with this drug. The treatment with Rituximab 
allowed an improvement in renal function. However, a 
longer follow-up period post-therapy (12 months) is 
needed to evaluate clinical response, since the relapse 
rate may be high. Rituximab therapy can induce a clinical 
response in 80% of patients (not transplanted) for refrac-
tory mixed cryoglobulinaemia secondary to hepatitis C 
virus infection22. The schedule and dosage recommend-
ed for this drug in renal transplant is not yet defined. 
The EUDRACT study (that did not include renal transplant 
patients)22 demonstrated that the low dose regimen (2 
weekly doses of 250 mg/m2) is as efficacious as the 
high dose regimen (4 weekly doses of 350 mg/m2) and 
is associated with less complications22.
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